Navigation Links
University of Colorado Cancer Center Review Shows Long-term Side-effects of New, Targeted Therapies in Pediatric Cancer Patients
Date:2/7/2013

Aurora, COLO (PRWEB) February 07, 2013

A University of Colorado Cancer Center review published this week in the journal Lancet Oncology describes possible long-term side-effects of new, targeted therapies in pediatric cancer patients: what we don’t know may hurt us.

“As pediatricians who treat kids with cancer, we expect the side-effects of traditional chemotherapies: low white blood count, infections, even long-term heart trouble or infertility. But there’s the impression that these new, molecularly targeted agents are much less toxic. That may be true, especially in adult patients, but until we have more information about the long-term effects of these therapies in children, we need to be careful about how and when we prescribe them,” says Chris Porter, MD, CU Cancer Center investigator and assistant professor of Pediatrics at the University of Colorado School of Medicine.

Already we know that molecularly targeted therapies may stunt the growth of pediatric patients, delay puberty or speed the onset of diabetes. And researchers are just now starting to ask about additional, sometimes unforeseen side-effects, potentially including more subtle issues such as neurocognitive, balance and motor defects.

“The growth of cancer cells isn’t that different than the growth of a 7-pound baby into a 210-pound teenage linebacker. Now, you shut down these growth pathways in an adult and it might not be a big deal, but you shut down these same pathways at a critical time in childhood development and you can have real problems,” says Lia Gore, MD, CU Cancer Center investigator and associate professor of Pediatrics and Medical Oncology at the CU School of Medicine.

The practical problem is this: FDA approval of many of these drugs for adult use allows physicians to prescribe the same drugs for pediatric use. Many are pills – orally administered, outpatient treatments that make it difficult to recognize and track p
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Elsevier and Kanazawa University in Japan Collaborate to Map Universitys Research Performance
2. Two University of Colorado Cancer Center Studies Show that Silibinin, Found in Milk Thistle, Protects Against UV-Induced Skin Cancer
3. WaferGens MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center
4. NextBio Teams With Emory University and the Aflac Cancer Center to Improve Outcomes for Children with Medulloblastoma
5. Notre Dame to be part of $194 million university research center network
6. University of Minnesota awarded $28 million grant to lead microelectronics development
7. Krishagni Enables University of New South Wales (Australia) to Adopt caTissue Plus
8. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
9. Rice University discovers that graphene oxide soaks up radioactive waste
10. Carin Grings remains identified by researchers at Uppsala University
11. Nanonex Delivered Advanced Nanoimprint Tool NX-B200 to Swinburne University of Technology, Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital IQ ... Stock Report coverage on MabVax Therapeutics Holdings Inc . ... a clinical stage biotechnology company focused on the development ... needs in the treatment of cancer. MabVax has discovered ... the protective immune responses generated by patients who have ...
(Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
(Date:2/26/2015)...  23andMe, the leading personal genetics company, today announced ... Officer and Corporate Counsel. Black brings a strong background ... as health care regulations. As a member of the ... reviewing, updating and enhancing the company,s privacy and consent ... joined the company January 5, 2015 and reports to ...
(Date:2/26/2015)... , Feb. 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... life sciences company that develops and commercializes proprietary technologies ... financial and operational results for the fiscal first quarter ... release are in Canadian dollars (CAD), unless otherwise stated. ... to win new business from our existing customers and ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 323andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... regenerative medicine company developing solutions based on the products of newborn ... Report as part of the 21st Century Breakthroughs for Biomedical Research ... ... -- Histogen, Inc., a regenerative medicine company developing solutions based on ...
... CITY, New Jersey, December 5, Rosetta Genomics, Ltd. (NASDAQ: ... microRNAs as biomarkers,reported today its consolidated financial results for ... The company recorded ... revenues were recorded from the date of acquisition of ...
... Bulletin Board: FVRL) and MyMedicalRecords.com, Inc. ("MMR"), a health,information ... Records (PHRs), announced today that two significant conditions,required for ... met. , (Logo: ... "We are pleased to announce that Favrille ...
Cached Biology Technology:Histogen Featured on Economic Report Television Series 2Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 2Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 3Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 4Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 5Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 6Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 7Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 8Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 9Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 10Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 2Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 3Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 4Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 5
(Date:2/5/2015)... Carolina , 5. Februar 2015 /PRNewswire/ ... als spezialisiertes Logistikunternehmen und hat eine neue ... klinische Logistikfirma (Clinical Logistics Organization – CLO) ... neuen Kampagne lautet First , mit ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition of ... to their offering. , The primary goal ... who she/he is claiming to be, and for this purpose, ... characteristics, such as fingerprint, hand or palm print, iris, face ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... a founding member of the Genome-Wide RNAi Global Initiative, ... to speed scientific and medical discoveries that target genes ... by Dharmacon, Inc. , manufacturer of the first ... interfering ribonucleic acid sequences. The library is designed to ...
... have helped eradicate and tame some of history's worst infectious ... vaccines can help overcome. The challenges society needs to ... plagues of the 21st century are the focus of a ... success of vaccines in controlling disease has been profound. ...
... of death among American men. It is estimated ... one in six males will develop the disease during his lifetime. However, ... disease. , One of the most innovative of these treatments is robotic-assisted ... is currently one of only ...
Cached Biology News:Yale participates in global human genome initiative 2Report focuses on challenges to unlocking future promise of vaccines 2Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer 2Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer 3
... Mouse monoclonal [YPF19] to Yersinia ... to detect Yersinia pestis . ... from Yersinia pestis vaccine ... This antibody recognises Y.pestis F1 capsular ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Phospho-FADD (Ser194) Antibody (Human Specific)...
Biology Products: